Angiogenesis is crucial for tumor development and progression, and antiangiogenetic
therapy represents a promising approach for cancer treatment. Thus, the in-depth …

Targeting of tumor vasculature is a promising strategy for cancer treatment. Among
endothelial cell markers, Endoglin, a cell membrane glycoprotein, is emerging as an …

Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as
a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane …

Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and
its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been …

Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in
human cancer; however, a specific cell membrane marker for endothelial cells of tumor …

Angiogenesis is the propelling force for tumor growth and metastasis, and antiangiogenic
therapy represents one of the most promising modalities for cancer treatment. CD105 …

Endoglin (CD105) is an auxiliary receptor for members of the TFG-β superfamily. Whereas it
has been demonstrated that the deficiency of endoglin leads to minor and defective …

Some markers of angiogenic endothelial cells are emerging as targets for cancer therapy.
The present study compared the expression of CD105 with that of other endothelial markers …

Endoglin (CD105) is a cell membrane glycoprotein over‐expressed on highly proliferating
endothelial cells in culture, and on endothelial cells of angiogenetic blood vessels within …

Some markers of angiogenic endothelial cells are emerging as targets of cancer therapy.
The present study compares the expression of CD105 with that of other endothelial markers …